ReviewCurrent rheumatology reports2015
Immune-Mediated Necrotizing Myopathy: Update on Diagnosis and Management.
Review in Current rheumatology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 96 citations in OpenAlex.
- Review
- A severe and fatal course of statin-induced necrotizing autoimmune myopathy: a case report.Journal of medical case reports · 2026Article
- Immune-Mediated Necrotizing Myopathy: A Systematic Review of Antibody-Specific Mechanisms and Treatment Outcomes.Cureus · 2025Review
- Integrative Approaches to Myopathies and Muscular Dystrophies: Molecular Mechanisms, Diagnostics, and Future Therapies.International journal of molecular sciences · 2025Review
- Plasma Exchange in Anti-Signal Recognition Particle Myopathy: A Systematic Review and Combined Analysis of Patient Individual Data.Journal of personalized medicine · 2024Review
- Article
- Spontaneous Development of Immune-Mediated Necrotizing Myopathy (IMNM) After Chronic Use of Statins: A Case Report.Cureus · 2023Article
- Outcome predictors of immune-mediated necrotizing myopathy-a retrospective, multicentre study.Rheumatology (Oxford, England) · 2022Article
- A case of anti-HMGCR myopathy triggered by sodium/glucose co-transporter 2 (SGLT2) inhibitors.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Article
- Myositis-specific Antibodies: Overview and Clinical Utilization.Rheumatology and immunology research · 2022Review
- Anti-SRP immune-mediated necrotizing myopathy: A critical review of current concepts.Frontiers in immunology · 2022Review
- High-intensity strength training in patients with idiopathic inflammatory myopathies: a randomised controlled trial protocol.BMJ open · 2021Article
- Article
- Statin-induced autoimmune myopathy: a case report.European journal of hospital pharmacy : science and practice · 2021Article
- Rituximab in the treatment of immune-mediated necrotizing myopathy: a review of case reports and case series.Therapeutic advances in neurological disorders · 2021Review
- Immune-mediated necrotising myopathy in asymptomatic patients with high creatine kinase.BMJ case reports · 2020Article
- Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies.Journal of Korean medical science · 2020Article
- Muscle aches and pains: do I have leukemia?International journal of hematology · 2020Article
- Biologic therapy in the idiopathic inflammatory myopathies.Rheumatology international · 2020Review
- The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies.Clinical rheumatology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The idiopathic inflammatory myopathies (IIMs) comprise a group of autoimmune disorders that target skeletal muscle. They are characterized by typical laboratory and clinical features including muscle weakness, elevated muscle enzymes, characteristic histopathology of muscle biopsies, as well as electromyography abnormalities. The IIMs are divided into polymyositis, dermatomyositis, inclusion body myositis, nonspecific myositis, and immune-mediated necrotizing myopathy (IMNM). IMNM is distinguished by the absence of primary inflammation on muscle biopsy. IMNM may be associated with myositis-specific autoantibodies (i.e., anti-SRP and anti-HMGCR) and malignancy, in association with viral infections (HIV or hepatitis C), or in relation to other connective tissue diseases (i.e., scleroderma). Typical clinical findings such as severe muscle weakness, highly elevated creatine kinase (CK) levels, as well as resistance to conventional immunosuppressive therapy are associated with this subtype of IIM. This review provides an overview of this disease entity and focuses on its diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.